- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02248792
Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study.
September 22, 2014 updated by: C V Krishna, Narayana Medical College & Hospital
Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study.
Methotrexate (MTX) is considered the 'gold-standard' drug for the treatment of severe psoriasis.
Health-related quality of life (HRQOL) is impaired in patients with psoriasis, more so if disease is severe.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
AP
-
Nellore, AP, India, 524003
- Recruiting
- Narayana Med College and Hospital
-
Contact:
- Avisa Rao, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Age range 18 to 65 years Both sexes Severe plaque-type psoriasis (BSA >10% or PASI >12) -
Exclusion Criteria:
Pregnancy Lactation Malignancy or immunosuppression including HIV Liver disease Renal disease Non compliant Psychiatric illness Hypersensitivity to methotrexate in the past
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group A
Methotrexate 10mg orally once weekly
|
|
|
Active Comparator: Group B
Methotrexate 25mg orally once weekly
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Improvement in health related quality of life
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
comparison of improvement in health related quality of life between Group A and Group B
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: C V Krishna, MD, Narayana Medical College and Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2013
Primary Completion (Anticipated)
January 1, 2015
Study Registration Dates
First Submitted
September 22, 2014
First Submitted That Met QC Criteria
September 22, 2014
First Posted (Estimate)
September 25, 2014
Study Record Updates
Last Update Posted (Estimate)
September 25, 2014
Last Update Submitted That Met QC Criteria
September 22, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Skin Diseases, Papulosquamous
- Psoriasis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Methotrexate
Other Study ID Numbers
- NMCHDer
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Plaque Type Psoriasis
-
Usynova Pharmaceuticals Ltd.RecruitingPlaque Psoriasis | Moderate to Severe Plaque PsoriasisChina
-
Fresenius Kabi SwissBioSim GmbHMerck KGaA, Darmstadt, GermanyCompletedPsoriasis | Moderate to Severe Plaque Psoriasis | Plaque Type PsoriasisUnited States, Canada, Czechia, Hungary, Russian Federation, Bulgaria, Mexico, United Kingdom, Poland, Germany, Estonia, France
-
Dermavon Holdings LimitedNot yet recruitingModerate to Severe Plaque PsoriasisChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingSevere Plaque Psoriasis in Chinese Children
-
UCB Biopharma SRLActive, not recruitingModerate Chronic Plaque Psoriasis | Severe Chronic Plaque Psoriasis | Mixed Guttate/Plaque PsoriasisUnited States, Canada, Puerto Rico
-
Idera Pharmaceuticals, Inc.CompletedModerate to Severe Plaque Psoriasis | Actively Extending Plaque PsoriasisUnited States
-
UCB Biopharma SRLCompletedModerate to Severe Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Canada, Germany, Hungary, Poland, Taiwan, Russia, South Korea
-
Novartis PharmaceuticalsCompletedChronic Severe Plaque-type PsoriasisBelgium, Italy, Egypt, France, Hungary, Russian Federation, Germany, Israel, Spain, Japan, Estonia, United Kingdom, Poland, Colombia, United States, Latvia, Guatemala, Romania, Switzerland
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, France, Germany, Netherlands, Poland, Spain, United Kingdom, Turkey (Türkiye)
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Poland, Taiwan, United Kingdom, Russia, South Korea
Clinical Trials on Methotrexate
-
Mayo ClinicNational Institute on Aging (NIA); National Center for Advancing Translational... and other collaboratorsCompletedRheumatic Diseases
-
Assistance Publique Hopitaux De MarseilleNot yet recruiting
-
Henan Cancer HospitalRecruitingLeptomeningeal Metastasis From Lung CancerChina
-
ProtalixRecruiting
-
Centre Hospitalier Universitaire de NiceNot yet recruitingErosive Hand OsteoarthritisFrance
-
Bangladesh Medical UniversityCompletedJuvenile Idiopathic Arthritis | Polyarticular Juvenile Idiopathic Arthritis | Refractory Polyarticular Juvenile Idiopathic ArthritisBangladesh
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingMethotrexate | Synovitis of Knee | Osteo Arthritis of the KneeBangladesh
-
Clinica Dermatologica Arbache ltdaRecruiting
-
Ruijin HospitalRecruiting
-
Wake Forest University Health SciencesAlliance for Research and Innovations in Pediatric Oncology (ARISE) Cancer...Not yet recruitingOsteosarcoma in Children | Osteosarcoma in Adolescents and Young AdultsUnited States